Ramelteon

Ramelteon

• CAS Number: 196597-26-9
• UNSPSC Description: Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].
• Target Antigen: Melatonin Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: Cancer-programmed cell death
• Field of Research: Neurological Disease; Endocrinology; Cancer
• Assay Protocol: https://www.medchemexpress.com/ramelteon.html
• Purity: 99.87
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: O=C(NCC[C@H]1C2=C(C=CC3=C2CCO3)CC1)CC
• Molecular Weight: 259.349
• References & Citations: [1]Kato K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301-310.|[2]Mayer G, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32(3):351-360. |[3]Hirai K, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms. 2005;20(1):27-37.|[4]Miyamoto M, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep. 2004;27(7):1319-1325.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched